<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-id journal-id-type="hwp">jem</journal-id><journal-title-group><journal-title>The Journal of Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">20082771</article-id><article-id pub-id-type="doi">10.1084/jem.20082771</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Definitive Report</subject></subj-group></article-categories><title-group><article-title>The nuclear receptor PPAR&#x003b3; selectively inhibits Th17 differentiation in a T cell&#x02013;intrinsic fashion and suppresses CNS autoimmunity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Klotz</surname><given-names>Luisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Burgdorf</surname><given-names>Sven</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dani</surname><given-names>Indra</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Saijo</surname><given-names>Kaoru</given-names></name><xref ref-type="aff" rid="aff2">9</xref></contrib><contrib contrib-type="author"><name><surname>Flossdorf</surname><given-names>Juliane</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hucke</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alferink</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="aff1">3</xref><xref ref-type="aff" rid="aff1">4</xref></contrib><contrib contrib-type="author"><name><surname>Novak</surname><given-names>Natalija</given-names></name><xref ref-type="aff" rid="aff1">5</xref></contrib><contrib contrib-type="author"><name><surname>Beyer</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff1">6</xref></contrib><contrib contrib-type="author"><name><surname>Mayer</surname><given-names>Gunter</given-names></name><xref ref-type="aff" rid="aff1">7</xref></contrib><contrib contrib-type="author"><name><surname>Langhans</surname><given-names>Birgit</given-names></name><xref ref-type="aff" rid="aff1">8</xref></contrib><contrib contrib-type="author"><name><surname>Klockgether</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Waisman</surname><given-names>Ari</given-names></name><xref ref-type="aff" rid="aff3">10</xref></contrib><contrib contrib-type="author"><name><surname>Eberl</surname><given-names>Gerard</given-names></name><xref ref-type="aff" rid="aff4">11</xref></contrib><contrib contrib-type="author"><name><surname>Schultze</surname><given-names>Joachim</given-names></name><xref ref-type="aff" rid="aff1">6</xref></contrib><contrib contrib-type="author"><name><surname>Famulok</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1">7</xref></contrib><contrib contrib-type="author"><name><surname>Kolanus</surname><given-names>Waldemar</given-names></name><xref ref-type="aff" rid="aff1">5</xref></contrib><contrib contrib-type="author"><name><surname>Glass</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff2">9</xref></contrib><contrib contrib-type="author"><name><surname>Kurts</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Knolle</surname><given-names>Percy A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Institutes of Molecular Medicine and Experimental Immunology</institution>; <label>2</label><institution>Department of Neurology</institution>; <label>3</label><institution>Department of Psychiatry</institution> and <label>4</label><institution>Institute of Molecular Psychiatry; Life and Medical Sciences Institute</institution> for <label>5</label><institution>Molecular Immunology</institution>, for <label>6</label><institution>Genomics and Immunoregulation</institution>, and for <label>7</label><institution>Chemical Biology</institution>; and <label>8</label><institution>Department of Internal Medicine, University of Bonn, Bonn 53105, Germany</institution></aff><aff id="aff2"><label>9</label><institution>Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093</institution></aff><aff id="aff3"><label>10</label><institution>Department of Internal Medicine, University of Mainz, Mainz 55131, Germany</institution></aff><aff id="aff4"><label>11</label><institution>Institute Pasteur, Laboratory of Lymphoid Tissues, Centre National de la Recherche Scientifique URA1961, Paris 75724, France</institution></aff><author-notes><corresp>CORRESPONDENCE Percy Knolle: <email>percyknolle@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>28</day><month>9</month><year>2009</year></pub-date><volume>206</volume><issue>10</issue><fpage>2079</fpage><lpage>2089</lpage><history><date date-type="received"><day>10</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 Klotz et al.</copyright-statement><copyright-year>2009</copyright-year><license license-type="openaccess" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This article is distributed under the terms of an Attribution&#x02013;Noncommercial&#x02013;Share Alike&#x02013;No Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.jem.org/misc/terms.shtml">http://www.jem.org/misc/terms.shtml</ext-link>). After six months it is available under a Creative Commons License (Attribution&#x02013;Noncommercial&#x02013;Share Alike 3.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link>).</license-p></license></permissions><abstract><p>T helper cells secreting interleukin (IL)-17 (Th17 cells) play a crucial role in autoimmune diseases like multiple sclerosis (MS). Th17 differentiation, which is induced by a combination of transforming growth factor (TGF)-&#x003b2;/IL-6 or IL-21, requires expression of the transcription factor retinoic acid receptor&#x02013;related orphan receptor &#x003b3;t (ROR&#x003b3;t). We identify the nuclear receptor peroxisome proliferator&#x02013;activated receptor &#x003b3; (PPAR&#x003b3;) as a key negative regulator of human and mouse Th17 differentiation. PPAR&#x003b3; activation in CD4<sup>+</sup> T cells selectively suppressed Th17 differentiation, but not differentiation into Th1, Th2, or regulatory T cells. Control of Th17 differentiation by PPAR&#x003b3; involved inhibition of TGF-&#x003b2;/IL-6&#x02013;induced expression of ROR&#x003b3;t in T cells. Pharmacologic activation of PPAR&#x003b3; prevented removal of the silencing mediator for retinoid and thyroid hormone receptors corepressor from the ROR&#x003b3;t promoter in T cells, thus interfering with ROR&#x003b3;t transcription. Both T cell&#x02013;specific PPAR&#x003b3; knockout and endogenous ligand activation revealed the physiological role of PPAR&#x003b3; for continuous T cell&#x02013;intrinsic control of Th17 differentiation and development of autoimmunity. Importantly, human CD4<sup>+</sup> T cells from healthy controls and MS patients were strongly susceptible to PPAR&#x003b3;-mediated suppression of Th17 differentiation. In summary, we report a PPAR&#x003b3;-mediated T cell&#x02013;intrinsic molecular mechanism that selectively controls Th17 differentiation in mice and in humans and that is amenable to pharmacologic modulation. We therefore propose that PPAR&#x003b3; represents a promising molecular target for specific immunointervention in Th17-mediated autoimmune diseases such as MS.</p></abstract></article-meta></front><body><p>CD4<sup>+</sup> T helper (Th) cells differentiate into discrete subsets, which can be discriminated on the basis of their cytokine expression profiles. Besides the &#x0201c;classical&#x0201d; CD4<sup>+</sup> T cell subsets (i.e., Th1, Th2, and regulatory T cells), a new subset characterized by secretion of IL-17 was identified (<xref ref-type="bibr" rid="bib12">Harrington et al., 2005</xref>; <xref ref-type="bibr" rid="bib29">Park et al., 2005</xref>). Th17 cells provide protection in certain infections, but more importantly, have been linked to development of autoimmunity, a function previously assigned to Th1 cells (<xref ref-type="bibr" rid="bib1">Bettelli et al., 2007</xref>). Th17 cells mediate pathology in several mouse models of autoimmunity, such as experimental autoimmune encephalomyelitis (EAE), inflammatory bowel disease, and collagen-induced arthritis (<xref ref-type="bibr" rid="bib5">Cua et al., 2003</xref>; <xref ref-type="bibr" rid="bib26">Murphy et al., 2003</xref>; <xref ref-type="bibr" rid="bib40">Yen et al., 2006</xref>). Recent studies have addressed the role of Th17 cells in human autoimmunity (<xref ref-type="bibr" rid="bib23">Lock et al., 2002</xref>; <xref ref-type="bibr" rid="bib35">Tzartos et al., 2008</xref>). Th17 differentiation critically depends on TGF-&#x003b2;, together with proinflammatory cytokines such as IL-6 or IL-21 (<xref ref-type="bibr" rid="bib18">Ivanov et al., 2006</xref>; <xref ref-type="bibr" rid="bib38">Yang et al., 2008</xref>). The key transcription factor for Th17 differentiation is retinoic acid (RA) receptor&#x02013;related orphan receptor &#x003b3;t (ROR&#x003b3;t; <xref ref-type="bibr" rid="bib18">Ivanov et al., 2006</xref>; <xref ref-type="bibr" rid="bib24">Manel et al., 2008</xref>). However, little information exists on the T cell&#x02013;intrinsic molecular mechanisms controlling ROR&#x003b3;t activity, thus contributing to control of Th17-mediated autoimmunity.</p><p>We and others have previously shown that the nuclear receptor peroxisome proliferator&#x02013;activated receptor &#x003b3; (PPAR&#x003b3;) is a negative regulator of dendritic cell maturation and function, thereby contributing to CD4<sup>+</sup> T cell anergy in vivo (<xref ref-type="bibr" rid="bib20">Klotz et al., 2007</xref>; <xref ref-type="bibr" rid="bib34">Szatmari et al., 2007</xref>). PPAR&#x003b3; has also been reported to influence the function of Th cell clones (<xref ref-type="bibr" rid="bib4">Clark et al., 2000</xref>); however, the influence of PPAR&#x003b3; on Th differentiation has not yet been addressed. Upon ligand binding, PPAR&#x003b3; heterodimerizes with the retinoid X receptor and binds to the PPAR response elements (PPRE) located in the promotor region of target genes (<xref ref-type="bibr" rid="bib30">Pascual et al., 2005</xref>; <xref ref-type="bibr" rid="bib11">Glass and Ogawa, 2006</xref>). Additionally, the antiinflammatory effects of PPAR&#x003b3; are mediated by negative interference with proinflammatory cell signaling, e.g., stabilization of corepressor complexes, such as nuclear corepressor (NCoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT; <xref ref-type="bibr" rid="bib30">Pascual et al., 2005</xref>; <xref ref-type="bibr" rid="bib33">Straus and Glass, 2007</xref>). PPAR&#x003b3; agonists include endogenous ligands such as the linoleic acid derivative 13s-hydroxyoctadecadienoic acid (HODE) produced by 12/15-lipoxygenase, as well as several synthetic agonistic ligands such as the antidiabetic thiazolidinediones, e.g., pioglitazone (PIO; <xref ref-type="bibr" rid="bib16">Huang et al., 1999</xref>; <xref ref-type="bibr" rid="bib33">Straus and Glass, 2007</xref>). Previous studies demonstrated a beneficial role of PPAR&#x003b3; in EAE (<xref ref-type="bibr" rid="bib27">Niino et al., 2001</xref>; <xref ref-type="bibr" rid="bib6">Diab et al., 2002</xref>; <xref ref-type="bibr" rid="bib8">Feinstein et al., 2002</xref>). These findings prompted us to address the question of whether PPAR&#x003b3; is involved in the T cell&#x02013;intrinsic control of Th17 responses.</p><sec><title>RESULTS AND DISCUSSION</title><sec><title>Control of Th17 differentiation by PPAR&#x003b3;</title><p>We first investigated the influence of PPAR&#x003b3; on the Th17 responses during MOG-induced EAE. Pharmacological activation of PPAR&#x003b3; with PIO in vivo ameliorated the disease course over the entire observation period (<xref ref-type="fig" rid="fig1">Fig. 1 a</xref>), as previously reported (<xref ref-type="bibr" rid="bib27">Niino et al., 2001</xref>; <xref ref-type="bibr" rid="bib6">Diab et al., 2002</xref>; <xref ref-type="bibr" rid="bib8">Feinstein et al., 2002</xref>). Importantly, CD4<sup>+</sup> T cells isolated from the central nervous system (CNS) of PIO-treated EAE mice at day 17 after disease induction produced significantly less IL-17A after PMA/ionomycin restimulation (<xref ref-type="fig" rid="fig1">Fig. 1 b</xref>). This prompted us to investigate in more detail the influence of PPAR&#x003b3; on the function of autoreactive MOG-specific T cells. We therefore determined the frequency of antigen-specific Th17 cells in the CNS by ELISpot. After MOG<sub>35-55</sub>-peptide specific stimulation of equal numbers of CNS-derived T cells, we observed a strong reduction in antigen-specific IL-17 producing, but interestingly not IFN-&#x003b3; producing, CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig1">Fig. 1</xref>). In light of these results, we next investigated the influence of PPAR&#x003b3; on CD4<sup>+</sup> Th differentiation. To focus exclusively on the effect of PPAR&#x003b3; in T cells, we used stimulation with &#x003b1;CD3/&#x003b1;CD28 in the absence of antigen-presenting cells. Interestingly, PPAR&#x003b3; activation by PIO selectively inhibited Th17 differentiation induced by TGF-&#x003b2; and IL-6, whereas IL-12&#x02013;induced Th1 differentiation was completely unaffected (<xref ref-type="fig" rid="fig1">Fig. 1 d</xref>; <ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082771/DC1">Fig. S1</ext-link>). To obtain unequivocal evidence for the role of PPAR&#x003b3; for Th17 differentiation, we generated T cell&#x02013;specific PPAR&#x003b3; knockout mice by crossing CD4-Cre mice with mice carrying loxP sites within the PPAR&#x003b3; gene (CD4-PPAR&#x003b3;<sup>KO</sup>; <ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082771/DC1">Fig. S2</ext-link>). In the absence of PPAR&#x003b3;, Th17 differentiation was strongly increased when compared with wild-type CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig1">Fig. 1 d</xref>), indicating that PPAR&#x003b3; serves as a T cell&#x02013;intrinsic brake of Th17 differentiation under physiological conditions. Accordingly, Th1 differentiation was not altered in CD4-PPAR&#x003b3;<sup>KO</sup> T cells (<xref ref-type="fig" rid="fig1">Fig. 1 d</xref>). Interestingly, the endogenous PPAR&#x003b3; agonist 13s-HODE, a linoleic acid derivative (<xref ref-type="bibr" rid="bib16">Huang et al., 1999</xref>), equally suppressed Th17, but not Th1, differentiation (<xref ref-type="fig" rid="fig1">Fig. 1 d</xref>), further indicating that PPAR&#x003b3; activity limits Th17 differentiation under physiological conditions. Given the fact that 12/15-lipoxygenase is expressed in T cells (<xref ref-type="bibr" rid="bib36">Vanderhoek, 1988</xref>), it is reasonable to assume that endogenous ligands produced by T cells themselves serve as a brake for Th17 differentiation in an autocrine fashion. Also, PPAR&#x003b3; ligand production by antigen-presenting cells may contribute to local control of Th17 differentiation (<xref ref-type="bibr" rid="bib16">Huang et al., 1999</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><p><bold>Control of Th17 differentiation by PPAR&#x003b3;.</bold> (a) MOG-EAE was induced in PIO or vehicle-treated wild-type mice (<italic>n</italic> = 6 per group, 3 experiments), and the clinical disease score was assessed daily. (b) In a separate experiment, mice were sacrificed at the peak of disease (day 18), CD4<sup>+</sup> T cells were isolated from the CNS, restimulated with PMA/ionomycin, and analyzed by flow cytometry gated on CD4<sup>+</sup> T cells; representative dot plots and mean results &#x000b1; SEM from four animals per group are shown; data are from two experiments. (c) CD4<sup>+</sup> T cells from the CNS were restimulated with MOG<sub>35-55</sub>-loaded DCs, and numbers of IL-17 and of IFN-&#x003b3;&#x02013;producing cells per 3 &#x000d7; 10<sup>4</sup> CD4<sup>+</sup> T cells were determined by ELISpot analysis. Graphs denote mean &#x000b1; SEM of all animals (<italic>n</italic> = 6 per group, 2 experiments). (d) Purified CD4<sup>+</sup> T cells from CD4-PPAR&#x003b3;<sup>KO</sup> mice or WT littermates were treated with PIO or the endogenous PPAR&#x003b3; agonist 13s-HODE, and Th17 differentiation was induced by stimulation for 72 h (top row). Alternatively, Th1 differentiation was induced for 72 h (bottom row). Cytokine-producing cells were determined by flow cytometry after PMA/ionomycin restimulation. Only living cells were analyzed by using LIVE/DEAD stain and exclusion of autofluorescence (x axis). Numbers denote mean percentage &#x000b1; SEM. (e) Th17 differentiation was induced as above and TNF, IL-17A, and IL-22 expression were determined by flow cytometry. Numbers denote mean percentage &#x000b1; SEM. (f) Th17 differentiation was induced as above; after 72 h expression of IL-17A, IL-17F, IL-21, and IL-23R were measured by quantitative real-time RT-PCR normalized to &#x003b2;-actin levels. (g) Additionally, CCR6-expression was determined by flow cytometry; CCL20-release was assessed by ELISA. (d&#x02013;g) One out of at least three independent experiments is shown.</p></caption><graphic xlink:href="JEM_20082771_GS_Fig1"/></fig><p>We further substantiated the inhibitory effect of PPAR&#x003b3; on Th17 differentiation by investigating other classical markers of Th17 cells. In addition to IL-17A, we found that PPAR&#x003b3; activation by PIO suppressed expression of TNF and IL-22 (<xref ref-type="fig" rid="fig1">Fig. 1 e</xref>), as well as IL-17F, IL-21, and IL-23R, in T cells (<xref ref-type="fig" rid="fig1">Fig. 1 f</xref>). Likewise, expression of the chemokine receptor CCR6 and its ligand CCL20 were also strongly controlled by PPAR&#x003b3; activation (<xref ref-type="fig" rid="fig1">Fig. 1 g</xref>). This demonstrates that PPAR&#x003b3;, indeed, influenced differentiation of Th17 cells rather than merely suppressing IL-17A production.</p></sec><sec><title>Selectivity of PPAR&#x003b3; for Th17 differentiation</title><p>To further characterize the specificity of PPAR&#x003b3; on the differentiation of Th17 cells, we evaluated the effect of PIO on cytokine-induced CD4<sup>+</sup> T cell differentiation into Th1, Th2, or regulatory T cells. Importantly, PIO did not modulate TGF-&#x003b2;&#x02013;mediated induction of Foxp3<sup>+</sup> regulatory T cells, IL-4&#x02013;mediated induction of Th2 cells, or IL-12&#x02013;mediated induction of Th1 cells (<xref ref-type="fig" rid="fig2">Fig. 2 a</xref>). This is in contrast to the effect of RA, which is a natural ligand of the nuclear RA receptor (<xref ref-type="bibr" rid="bib2">Chambon, 1994</xref>) that has been shown to reciprocally regulate Th17 and regulatory T cell differentiation (<xref ref-type="bibr" rid="bib25">Mucida et al., 2007</xref>). In direct comparison, RA and PIO both efficiently suppressed Th17 differentiation, whereas RA but not PIO induced TGF-&#x003b2;&#x02013;mediated expression of Foxp3 (<xref ref-type="fig" rid="fig2">Fig. 2 a</xref>). Accordingly, CD4-PPAR&#x003b3;<sup>KO</sup> T cells did not show altered TGF-&#x003b2;&#x02013;mediated Foxp3-induction (unpublished data). A further distinction between RA and PIO was observed on Th1 differentiation, as RA slightly but significantly impeded IL-12&#x02013;mediated induction of IFN-&#x003b3; expression in T cells (<xref ref-type="fig" rid="fig2">Fig. 2 a</xref>), as has been previously reported (<xref ref-type="bibr" rid="bib19">Iwata et al., 2003</xref>). Collectively, these data indicate that distinct molecular mechanisms were involved in PPAR&#x003b3;-mediated, as compared with RA-mediated, control of T cell differentiation.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><p><bold>Selectivity of PPAR&#x003b3; for Th17 differentiation.</bold> (a) CD4<sup>+</sup> T cells were subjected to Th1, Th2, Th17, and regulatory T cell differentiation protocols, as described in the Materials and methods section, and the influence of RA and PIO on the induction of lineage markers was determined by flow cytometry and analyzed as described in Materials and methods. (b) CD4<sup>+</sup> T cell differentiation was induced as described in Materials and methods, and the influence of PIO on expression of the lineage-determining transcription factors T-bet, GATA-3, ROR&#x003b3;t, and Foxp3 was determined by quantitative real-time PCR and normalized to &#x003b2;-actin levels after 48 h. Data in a and b are representative of at least three independent experiments.</p></caption><graphic xlink:href="JEM_20082771_GS_Fig2"/></fig><p>We next investigated whether PPAR&#x003b3; also affected expression of the key transcription factors determining CD4<sup>+</sup> T cell differentiation. PPAR&#x003b3;-activation selectively suppressed TGF-&#x003b2;/IL-6&#x02013;mediated expression of ROR&#x003b3;t, the transcription factor required for Th17 induction, whereas the expression of the transcription factors determining Th1, Th2, and regulatory T cell differentiation, i.e., T-bet, GATA-3, and FoxP3, was not influenced by PIO (<xref ref-type="fig" rid="fig2">Fig. 2 b</xref>), again confirming that PPAR&#x003b3; acted specifically on the differentiation of Th17 cells. Other transcriptional regulators have been reported to influence Th17 differentiation. Foxp3 has been shown to directly antagonize ROR&#x003b3;t activity, and thus prevent Th17 differentiation (<xref ref-type="bibr" rid="bib41">Zhou et al., 2008</xref>). Furthermore, several groups have reported that the aryl hydrocarbon receptor elicits either regulatory T cell or Th17 responses when activated by distinct ligands; however, the underlying mechanisms do not seem to involve ROR&#x003b3;t regulation (<xref ref-type="bibr" rid="bib31">Quintana et al., 2008</xref>; <xref ref-type="bibr" rid="bib37">Veldhoen et al., 2008</xref>). Additionally, the nuclear orphan receptor NR2F6 seems to regulate Th17-dependent autoimmunity, but with no apparent involvement of ROR&#x003b3;t (<xref ref-type="bibr" rid="bib15">Hermann-Kleiter et al., 2008</xref>). It can therefore be concluded that several receptors are involved in the T cell&#x02013;intrinsic control of Th17-responses, but that the molecular pathways involved in these processes are distinct. Even among the family of PPARs, the regulatory effect on Th17 differentiation is not a general feature, as lack of PPAR&#x003b1; in T cells did not result in altered IL-17 expression levels (<xref ref-type="bibr" rid="bib7">Dunn et al., 2007</xref>).</p></sec><sec><title>PPAR&#x003b3; inhibits Th17 differentiation by controlling ROR&#x003b3;t induction</title><p>We next evaluated whether PPAR&#x003b3; influenced ROR&#x003b3;t expression in T cells. In PPAR&#x003b3;<sup>KO</sup> T cells, we observed enhanced cytokine-induced ROR&#x003b3;t induction compared with PPAR&#x003b3;<sup>WT</sup> T cells (<xref ref-type="fig" rid="fig3">Fig. 3 a</xref>). The suppressive effect of PPAR&#x003b3; activation by PIO on the one hand and the increased expression of ROR&#x003b3;t in PPAR&#x003b3;<sup>KO</sup> T cells on the other hand illustrate the dynamic range of PPAR&#x003b3;-mediated control of Th17 differentiation. We substantiated the influence of PPAR&#x003b3; activation on ROR&#x003b3;t expression using reporter mice, which express GFP under control of the RORc(&#x003b3;t) promoter (<xref ref-type="bibr" rid="bib22">Lochner et al., 2008</xref>). In such T cells, we observed that PIO strongly reduced TGF-&#x003b2;/IL-6&#x02013;mediated GFP-expression (<xref ref-type="fig" rid="fig3">Fig. 3 b</xref>). Importantly, both the frequency of GFP<sup>pos</sup> T cells and the mean fluorescence intensity of GFP-expressing T cells were reduced by PIO (<xref ref-type="fig" rid="fig3">Fig. 3, b and c</xref>). These results indicated that most CD4<sup>+</sup> T cells failed to express ROR&#x003b3;t under the influence of PPAR&#x003b3; activation, thus giving rise to less Th17 cells. Furthermore, the decreased mean fluorescence intensity of GFP in PIO-treated RORc(&#x003b3;t) reporter T cells (<xref ref-type="fig" rid="fig3">Fig. 3 c</xref>) revealed that upon PPAR&#x003b3; activation there was less GFP, i.e., ROR&#x003b3;t, on a per cell basis, suggesting that PPAR&#x003b3; reduced ROR&#x003b3;t transcription on a single-cell level.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><p><bold>PPAR&#x003b3; inhibits Th17 differentiation by controlling ROR&#x003b3;t induction.</bold> (a) Th17 differentiation from PPAR&#x003b3;<sup>KO</sup> and wild-type T cells was induced as described in Materials and methods; ROR&#x003b3;t expression was determined by quantitative real-time PCR and normalized to &#x003b2;-actin levels. (b and c) CD4<sup>+</sup> T cells from Rorc(&#x003b3;t)-GFP<sup>TG</sup> reporter mice were treated with PIO, and Th17 differentiation was induced. After 14 h, GFP<sup>&#x02212;</sup> expression was assessed by flow cytometry and analyzed for frequency of GFP<sup>pos</sup> cells (b) and for MFI of GFP-expressing cells (c). One out of three independent experiments is shown. (d) PPAR&#x003b3; was recombinantly expressed (<ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082771/DC1">Fig. S3 a</ext-link>), and interaction of recombinant PPAR&#x003b3; with the murine ROR&#x003b3;t promoter was determined by surface plasmon resonance analysis. Sensograms show the binding of indicated concentrations of PPAR&#x003b3; at either the ROR&#x003b3;t promoter or the murine AP2 promoter containing a bona fide PPRE site as positive control; shown are a representative sensogram (left) and a quantitative analysis (right). The bar graph shows mean &#x000b1; SEM from three independent experiments. (e) Signal-dependent clearance of SMRT from the ROR&#x003b3;t promoter is prevented by PIO. ChIP experiments were performed for SMRT in mock-treated CD4<sup>+</sup> T cells and in CD4<sup>+</sup> T cells stimulated with TGF-&#x003b2;/IL6 in the presence or absence of PIO. ChIP assay was performed with &#x003b1;SMRT or IgG for control of specificity. Immunoprecipitated DNA was analyzed by quantitative PCR using primers specific for the ROR&#x003b3;t promoter; as control, binding of SMRT to a nonrelated DNA control (exon 1 of the ROR&#x003b3; gene) was investigated and set as 1. Two independent experiments were performed, and mean results &#x000b1; SEM are shown.</p></caption><graphic xlink:href="JEM_20082771_RGB_Fig3"/></fig><p>The control of PPAR&#x003b3; over ROR&#x003b3;t transcription led us to examine whether the ROR&#x003b3;t promoter contained a bona fide PPAR&#x003b3;-binding site (PPRE), which might permit direct interaction of PPAR&#x003b3; with the ROR&#x003b3;t promoter. Bioinformatic analysis did not reveal any known PPRE sequence within the mouse ROR&#x003b3;t promoter (unpublished data). In addition, we excluded direct interaction of PPAR&#x003b3; with the ROR&#x003b3;t promoter by examining the binding of recombinant PPAR&#x003b3; to the full-length ROR&#x003b3;t promoter using surface plasmon resonance analysis. In contrast to strong and specific binding of PPAR&#x003b3; to the AP2 promoter, which contains a PPRE site (<xref ref-type="bibr" rid="bib9">Frohnert et al., 1999</xref>), we did not observe significant binding to the ROR&#x003b3;t promoter (<xref ref-type="fig" rid="fig3">Fig. 3 d</xref>).</p><p>The lack of a high-affinity PPAR&#x003b3; binding site in the ROR&#x003b3;t promoter raised the possibility that PPAR&#x003b3; might negatively regulate ROR&#x003b3;t transcription through a transrepression mechanism that does not require direct DNA binding. One such mechanism involves the ability of ligand-activated PPAR&#x003b3; to inhibit signal-dependent clearance of NCoR or SMRT corepressor complexes from promoters of regulated genes (<xref ref-type="bibr" rid="bib30">Pascual et al., 2005</xref>; <xref ref-type="bibr" rid="bib10">Ghisletti et al., 2009</xref>). To investigate this possibility, we used chromatin immunoprecipitation (ChIP) to screen of genomic sequences surrounding the ROR&#x003b3;t promoter (unpublished data) for corepressor binding. These studies revealed the binding of the corepressor SMRT, but not NCoR, at the ROR&#x003b3;t promoter in unstimulated mouse CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig3">Fig. 3 e</xref> and not depicted). Importantly, stimulation of CD4<sup>+</sup> T cells with TGF-&#x003b2; and IL-6 resulted in rapid and nearly complete loss of SMRT from the ROR&#x003b3;t promoter (<xref ref-type="fig" rid="fig3">Fig. 3 e</xref>), indicating that SMRT clearance precedes ROR&#x003b3;t activation. Interestingly, this cytokine-induced clearance of SMRT from the ROR&#x003b3;t promoter was prevented by the PPAR&#x003b3; agonist PIO (<xref ref-type="fig" rid="fig3">Fig. 3 e</xref>). These data suggest that the retention of SMRT results in persistent repression of ROR&#x003b3;t in the presence of activating cytokines, and are consistent with prior studies demonstrating that PPAR&#x003b3; suppresses activation of inflammatory response genes in macrophages by preventing NCoR/SMRT turnover (<xref ref-type="bibr" rid="bib10">Ghisletti et al., 2009</xref>). Interference of SMRT clearance from the ROR&#x003b3;t promoter thus provides a previously unrecognized mechanism by which ligand-activated PPAR&#x003b3; may control Th17 differentiation in T cells. However, these findings do not exclude other mechanisms, such as modulation of STAT3 or IRF4 signaling (<xref ref-type="bibr" rid="bib28">Nurieva et al., 2007</xref>; <xref ref-type="bibr" rid="bib17">Huber et al., 2008</xref>).</p></sec><sec><title>PPAR&#x003b3; in T cells controls CNS autoimmunity and restricts Th17 differentiation in vivo</title><p>To analyze whether PPAR&#x003b3; is involved in T cell&#x02013;intrinsic control of CNS autoimmunity, we induced EAE in CD4-PPAR&#x003b3;<sup>KO</sup> mice and wild-type littermates. CD4-PPAR&#x003b3;<sup>KO</sup> mice showed a significantly earlier onset and aggravated disease course during the initial T cell&#x02013;dependent phase of disease until d15 (<xref ref-type="fig" rid="fig4">Fig. 4 a</xref>). However, this difference was not observed in the effector phase, when disease activity is mainly determined by a local inflammatory response within the CNS governed by microglial cells (<xref ref-type="bibr" rid="bib14">Heppner et al., 2005</xref>). Disease activity in CD4-PPAR&#x003b3;<sup>KO</sup> mice directly correlated with the total numbers of infiltrating CD4<sup>+</sup> T cells in the CNS (<xref ref-type="fig" rid="fig4">Fig. 4 b</xref>). Both at the beginning of clinical disease activity (day 8), and at the peak of disease in CD4-PPAR&#x003b3;<sup>KO</sup> mice (day 13), we found significantly increased total CD4<sup>+</sup> T cell numbers in the CNS. Later (day 18) disease score and T cell influx were not different from wild-type littermates. As expected, PIO-treated wild-type mice exhibited decreased T cell numbers within the CNS at all time points investigated (<xref ref-type="fig" rid="fig4">Fig. 4 b</xref>). Importantly, at the peak of disease in CD4-PPAR&#x003b3;<sup>KO</sup> mice, the frequency of MOG<sub>35-55</sub> peptide-specific, IL-17&#x02013;producing CD4<sup>+</sup> T cells in the CNS was increased by threefold, which, together with the increase in T cell influx, enhanced the numbers of IL-17&#x02013;producing autoreactive T cells within the target organ by nearly fivefold (<xref ref-type="fig" rid="fig4">Fig. 4, b and c</xref>). In contrast, there was no alteration in antigen-specific IFN-&#x003b3;&#x02013;producing CD4<sup>+</sup> T cells in these mice (<xref ref-type="fig" rid="fig4">Fig. 4 c</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><p><bold>PPAR&#x003b3; in T cells controls CNS autoimmunity and restricts Th17 differentiation in vivo.</bold> (a) MOG-EAE was induced in CD4-PPAR&#x003b3;<sup>KO</sup> mice and CD4-PPAR&#x003b3;<sup>WT</sup> littermates (<italic>n</italic> = 8 per group, 3 experiments), and the clinical disease score was assessed daily. (b) In a separate experiment, mice were sacrificed at indicated time points and mononuclear cells derived from the CNS of KO mice and WT littermates (&#x000b1; PIO) were analyzed by flow cytometry. Mean results from <italic>n</italic> = 4 animals per group and time point &#x000b1; SEM are shown; data are from 2 experiments. (c) CD4<sup>+</sup> T cells from spleens and CNS of each animal were restimulated with MOG<sub>35-55</sub>-loaded DCs, and numbers of IL-17 and of IFN-&#x003b3;&#x02013;producing cells per 3 &#x000d7; 10<sup>4</sup> CD4<sup>+</sup> T cells were determined by ELISpot analysis. Graphs denote mean &#x000b1; SEM of all animals (8 per group; 3 experiments). (d and e) 10<sup>6</sup> CD90.2<sup>+</sup> OT-II cells were adoptively transferred into congenic mice treated with PIO or vehicle alone (w/o Pio), followed by s.c. immunization with OVA/CFA (100 &#x000b5;g OVA/mouse). CD44 and CD62L expression levels, as well as IL-17A production upon restimulation with PMA/ionomycin, were assessed by flow cytometry at day 4. Six animals per group; shown are representative plots and mean results &#x000b1; SEM, from two experiments.</p></caption><graphic xlink:href="JEM_20082771_GS_Fig4"/></fig><p>The clinical symptoms and antigen-specific Th17 responses in CD4-PPAR&#x003b3;<sup>KO</sup> mice both revealed that the kinetics of CNS autoimmunity in vivo were modulated by PPAR&#x003b3; in a T cell&#x02013;intrinsic fashion. There was pronounced accumulation of IL-17&#x02013;producing T cells in the CNS compared with the spleen in CD4-PPAR&#x003b3;<sup>KO</sup> mice (<xref ref-type="fig" rid="fig4">Fig. 4 c</xref>), which may be caused by guided entry of Th17 cells into the CNS. A recent study demonstrated that CCR6-expressing Th17 cells function as &#x0201c;pioneer&#x0201d; cells, enabling immune cell entry into the CNS at the beginning of CNS autoimmunity (<xref ref-type="bibr" rid="bib32">Reboldi et al., 2009</xref>). In this regard, the control of expression of both CCR6 and its ligand CCL20 by PPAR&#x003b3; activation (<xref ref-type="fig" rid="fig1">Fig. 1 g</xref>) may explain the decreased influx of T cells and the reduced disease activity in the CNS of PIO-treated wild-type mice. The protective effect of PIO on disease activity was greatly diminished in CD4-PPAR&#x003b3;<sup>KO</sup> mice (<ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082771/DC1">Fig. S4 b</ext-link>), thus excluding off-target effects that had been reported previously (<xref ref-type="bibr" rid="bib3">Chawla et al., 2001</xref>) and further demonstrating that PPAR&#x003b3; expression in T cells was required for full protective effect of PIO on CNS autoimmunity. The observation that PPAR&#x003b3; activation in vivo did not entirely protect from EAE development, despite its profound effect on Th17 differentiation, lends support for a key but not exclusive role of Th17 cells in CNS inflammation, as previously reported (<xref ref-type="bibr" rid="bib39">Yang et al., 2009</xref>). The persistent Th1 responses, which were not altered by PPAR&#x003b3; activation, may explain persistent disease activity, despite diminished Th17 responses.</p><p>As we also observed a significant increase in antigen-specific Th17 cell numbers in the spleen in CD4-PPAR&#x003b3;<sup>KO</sup> mice at the peak of disease (<xref ref-type="fig" rid="fig4">Fig. 4 c</xref>), we next asked whether PPAR&#x003b3; influenced Th17 differentiation in vivo at early time points. To this end, we adoptively transferred CD90.2<sup>+</sup> CD4<sup>+</sup> T cells from OT-II mice, followed by immunization with OVA in CFA. Importantly, PIO treatment of these mice strongly interfered with the expression of activation markers (<xref ref-type="fig" rid="fig4">Fig. 4 d</xref>) and IL-17 production (<xref ref-type="fig" rid="fig4">Fig. 4 e</xref>) by the adoptively transferred T cells 4 d after immunization; this persisted for longer than 4 d (day 7; not depicted), demonstrating that PPAR&#x003b3; controls antigen-specific Th17 differentiation in vivo.</p><p>Collectively, the entire range of PPAR&#x003b3;-sensitive control of Th17 differentiation in vivo and CNS autoimmunity is reflected by the combination of pharmacological PPAR&#x003b3; activation on the one hand and by the absence of PPAR&#x003b3;-activity in CD4-PPAR&#x003b3;<sup>KO</sup> mice on the other hand.</p></sec><sec><title>PPAR&#x003b3; selectively controls Th17 differentiation in T cells from healthy controls (HCs) and MS patients</title><p>The protective effects of PPAR&#x003b3; on both clinical manifestation and Th17-responses during EAE prompted us to investigate whether T cells from HCs and MS patients were susceptible to treatment with PPAR&#x003b3; agonists. Again, we focused on the effect of PPAR&#x003b3; activation on T cells by using direct stimulation with TGF-&#x003b2;/IL-21 in the absence of antigen-presenting cells. Pharmacologic PPAR&#x003b3; activation reduced the frequency of IL-17A&#x02013;producing CD45RA<sup>+</sup> CD4<sup>+</sup> T cells both in HC and MS patients (<xref ref-type="fig" rid="fig5">Fig. 5 a</xref>). Although in our experiments there was no apparent difference in Th17 differentiation between HC and MS patients in vitro, it is important to note that PIO-treatment was equally effective in potent suppression of IL-17A release from T cells (<xref ref-type="fig" rid="fig5">Fig. 5 b</xref>). Moreover, no influence of PIO was observed during IFN-&#x003b3; production (<xref ref-type="fig" rid="fig5">Fig. 5 b</xref>). Pharmacologic PPAR&#x003b3; activation prevented Th17 differentiation, as demonstrated by diminished expression of the Th17 markers IL-17F, IL-21, IL-22, and IL-23R upon PIO treatment (<xref ref-type="fig" rid="fig5">Fig. 5 c</xref>). Importantly, the specific effect of PPAR&#x003b3; activation on Th17 induction in human CD4<sup>+</sup> T cells was further illustrated by selective regulation of ROR&#x003b3;t expression, whereas T-bet and GATA-3 expression were not altered by PIO (<xref ref-type="fig" rid="fig5">Fig. 5 d</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><p><bold>PPAR&#x003b3; selectively controls Th17 differentiation in T cells from HCs and MS patients.</bold> CD45RA<sup>+</sup> CD4<sup>+</sup> T cells from HC (<italic>n</italic> = 5) and from relapsing-remitting MS patient (<italic>n</italic> = 7) were treated with PIO and stimulated as described in Materials and methods. (a) IL-17A<sup>+</sup> cells from HC and MS-patients after restimulation with PMA/ionomycin were assessed by flow cytometry. (b) IL-17A and IFN-&#x003b3; secretion were determined by ELISA. Graphs show mean percentages &#x000b1; SEM from the separate experiments (<italic>n</italic> = 7). (c) CD4<sup>+</sup> T cells were activated as in a, and expression of IL-17F, IL-21, IL-22, and IL-23R was measured by real-time RT-PCR normalized to &#x003b2;-actin levels. (d) CD4<sup>+</sup> T cells were stimulated as described, and expression of ROR&#x003b3;t, T-bet, and GATA-3 after 72 h was measured by real-time PCR and normalized to &#x003b2;-actin levels. (c and d) One representative dataset out of three is shown.</p></caption><graphic xlink:href="JEM_20082771_GS_Fig5"/></fig><p>In summary, we identify PPAR&#x003b3; as a defined molecular target to selectively modulate Th17 differentiation in a T cell&#x02013;intrinsic fashion, which opens up new possibilities for specific immunointervention in Th17-mediated autoimmune diseases such as MS.</p></sec></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title/><sec><title>Mice.</title><p>CD4-specific PPAR&#x003b3; knockout mice with the genotype PPAR&#x003b3;<sup>fl/fl</sup> CD4-Cre<sup>+/&#x02212;</sup> (i.e., CD4-PPAR&#x003b3;<sup>KO</sup> mice) were generated by crossing PPAR&#x003b3;<sup>fl/fl</sup> mice (<xref ref-type="bibr" rid="bib13">He et al., 2003</xref>) with CD4-Cre<sup>+/&#x02212;</sup> transgenic mice expressing Cre recombinase under control of the CD4 enhancer/promoter/silencer (<xref ref-type="bibr" rid="bib21">Lee et al., 2001</xref>). Expression of Cre recombinase in CD4-expressing T cells leads to recombination at two loxP sites flanking exons two and three of the PPAR&#x003b3; gene, thus resulting in a T cell&#x02013;specific PPAR&#x003b3; knockout (Fig. S1). We did not observe any alteration in immune cell frequencies in these mice (Fig. S1). CD90.2<sup>+</sup> CD4-TCR transgenic OT II mice specific for the peptide ova<sub>323-339</sub>, BAC-transgenic Rorc(&#x003b3;t)-GFP<sup>TG</sup> mice, and C57BL/6 mice (Charles River Laboratories) were maintained under specific pathogen&#x02013;free conditions. All animal experiments were performed according to the guidelines of the animal ethics committee and were approved by the government authorities of Nordrhein-Westfalen, Germany.</p></sec><sec><title>Cell culture and adoptive cell transfer.</title><p>PBMCs were obtained from the peripheral blood of healthy volunteers or from patients with clinically definite relapsing-remitting MS according to the McDonald criteria, approved by the local Ethics Committee. CD4<sup>+</sup>CD45RA<sup>+</sup>CD45RO<sup>&#x02212;</sup>CD25<sup>&#x02212;</sup> T cells were isolated by immunomagnetic cell separation using an AutoMACS (Miltenyi Biotec) and stimulated with plate-bound 1.5 &#x000b5;g/ml &#x003b1;CD3 antibody (OKT3), 1 &#x000b5;g/ml &#x003b1;CD28 antibody (28.2), 2.5 ng/ml TGF-&#x003b2; (R&#x00026;D Systems) and 12.5 ng/ml IL-21 (Cell Systems) for 7 d in serum-free X-VIVO 15 medium (Biowhittaker; <xref ref-type="bibr" rid="bib38">Yang et al., 2008</xref>). 10 &#x000b5;M PIO (Enzo Biochem, Inc.) was added when indicated. Mouse splenic CD4<sup>+</sup> T cells were isolated by immunomagnetic separation using CD4-MACS beads (Miltenyi Biotec) and stimulated with plate-bound 4 &#x000b5;g/ml &#x003b1;CD3 antibody (145-2C11) and 4 &#x000b5;g/ml &#x003b1;CD28 antibody (3751) together with 5 ng/ml TGF-&#x003b2; and 20 ng/ml IL-6 (PeproTech) for Th17 differentiation; with IL-12 (10 ng/ml) for Th1 differentiation; with IL-4 (10 ng/ml) for Th2 differentiation or with TGF-&#x003b2; alone (5 ng/ml) for regulatory T cell differentiation. In one experiment, MACS-isolated splenic DCs from B6 mice were cocultured with T cells in the presence of antigen (10 &#x000b5;g/ml ova<sub>323-339</sub>). The endogenous PPAR&#x003b3; agonist 13s-HODE (Cayman Chemicals) was used at a concentration of 10 &#x000b5;M. All-trans RA (Sigma-Aldrich) was used at a 1 &#x000b5;M concentration. TCR transgenic CD4<sup>+</sup> T cells from OTII mice bearing the congenic marker CD90.1<sup>+</sup> were isolated and 10<sup>6</sup> cells were adoptively transferred by bolus i.v. injection in 200 &#x000b5;l PBS into wild-type CD90.2<sup>+</sup> congenic mice.</p></sec><sec><title>EAE.</title><p>EAE was induced by s.c. injecting 50 &#x000b5;g MOG<sub>35-55</sub> peptide (BIOTREND) emulsified in CFA (Difco) with 8 mg/ml heat-inactivated <italic>Mycobacterium tuberculosis</italic> and two i.p. injections of 200ng <italic>Bordetella pertussis toxin</italic> (List Biologicals) on days 0 and 2. Clinical assessment of EAE was performed daily using a scale ranging from 0 to 6: 0, clinically normal; 1, reduced tone of tail; 2, ataxia and/or slight hind-limb paresis; 3, severe hind-limb paresis; 4, hind limb plegia; 5, tetraparesis; 6, moribund/dead animals. Cell analysis from spleens and CNS was performed as indicated.</p></sec><sec><title>Real-time RT-PCR.</title><p>Cells were washed with ice-cold PBS, and RNA extraction was performed using the RNeasy mini kit (QIAGEN) according to the manufacturer&#x02019;s protocol. Reverse transcription of RNA was performed with SuperScript III (Invitrogen). cDNA was analyzed using FAM-labeled TaqMan probes obtained from Applied Biosystems and used according to the manufacturer&#x02019;s recommendations. mRNA expression levels of ROR&#x003b3;t, T-bet, GATA-3, and Foxp3, as well as the Th17 markers IL-17A, IL17F, IL-21, IL-22, and IL-23R, were assessed using gene-specific primers. Gene expression was assessed in triplicates and normalized to &#x003b2;-actin. Amplification of cDNA was performed on an AbiPrism 7900 HT cycler (Applied Biosystems).</p></sec><sec><title>Cytokine detection.</title><p>Mouse IL-17A and Foxp3 protein expression were examined by intracellular staining according to the manufacturer&#x02019;s protocol. MOG-specific IL-17 and IFN-&#x003b3; production was analyzed by specific ELISpot assays according to the manufacturer&#x02019;s procedures (R&#x00026;D Systems), and spot numbers were counted with an automated ELISpot reader (BIOREADER-2000). Human IL-17A and IFN-&#x003b3; protein levels from cell culture supernatants were determined by ELISA (R&#x00026;D Systems).</p></sec><sec><title>ChIP experiments.</title><p>ChIP assays were performed as previously described (<xref ref-type="bibr" rid="bib30">Pascual et al., 2005</xref>). Th17 differentiation was induced for the indicated time points before cross-linking for 10 min with 1% formaldehyde. Anti-SMRT (ABR) or control rabbit IgG (Santa Cruz Biotechnology, Inc.) were used for immunoprecipitation. A 150-bp region of the <italic>ROR&#x003b3;t</italic> promoter was amplified spanning the most proximal transcription start site. Quantitative PCR was performed with SYBR-GreenER (Invitrogen) and analyzed on a 7200 real time PCR system (ABI).</p></sec><sec><title>Surface plasmon resonance analysis.</title><p>6xHIS-PPAR&#x003b3; was recombinantly expressed in the bacterial strain <italic>Escherichia coli</italic> BL21, eluted, and desalted using a PD-10 column and 10% glycerol in PBS. The promoter sequences of mouse ROR&#x003b3;t and mouse AP2 were amplified by PCR using the oligonucleotides (5&#x02032;-GCTTCCCAATGGACACTTGCAAG-3&#x02032; and 5&#x02032;-AGGACAGCACACAGCTGGCAGTGG-3&#x02032; for ROR&#x003b3;t; and 5&#x02032;-TCTAGAAGGAAGAACCAGGG-3&#x02032; and 5&#x02032;-AGGCAGAAATGCACATTTCACC-3&#x02032; for AP2). For each reaction, one primer was biotinylated at the 5&#x02032; end. As negative control, a 2-kb fragment of the mouse mannose receptor was amplified. For SPR analysis of promotor binding, a Biacore 3000 (GE Healthcare) was used. In brief, 700&#x02013;1,000 RU of 5&#x02032;-biotinylated variants of the respective dsDNAs were immobilized on the surface of a SA-sensorchip (GE Healthcare) according to the manufacturer&#x02019;s instructions. As negative control, 2 kb of the mouse mannose receptor was used. PBS (pH 7.3) was used as running buffer, and the regeneration of the surface was accomplished by injecting 1 M Urea for 30 s. All measurements were done at a flow rate of 30 &#x000b5;l/min, and protein injections at indicated concentrations were conducted for 2 min using the &#x0201c;inject&#x0201d; mode. Measurements were done in the presence of 0.001 mg/ml heparin to reduce unspecific binding.</p></sec><sec><title>Online supplemental material.</title><p>Fig. S1 shows the Th17 differentation of highly purified naive CD4<sup>+</sup> T cells. Fig. S2 shows the generation of T cell&#x02013;specific PPAR&#x003b3; knockout mice and phenotypic characterization of immune cells. Fig. S3 shows the purification of recombinantly expressed full-length murine PPAR&#x003b3;; surface plasmon resonance analysis of PPAR&#x003b3;-binding to PPRE-oligonucleotides; and effect of PPAR&#x003b3; on SMRT-binding to the ROR&#x003b3;t promoter in the absence of Th17 inducing conditions. Fig. S4 shows the effect of the CD4-Cre transgene on EAE disease course and the absence of a protective PIO effect in CD4-PPAR&#x003b3;<sup>KO</sup> mice. Online supplemental material is available at <ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082771/DC1">http://www.jem.org/cgi/content/full/jem.20082771/DC1</ext-link>.</p></sec></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>[Supplemental Material]</title></caption><media mimetype="text" mime-subtype="html" xlink:href="jem.20082771_index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="jem.20082771_1.pdf"/></supplementary-material></sec></body><back><ack><p>We would like to acknowledge the excellent technical assistance of N. Kuhn, C. Mandel, J. Collier, and J. Birke. Moreover, we acknowledge the assistance of the Flow Cytometry Core Facility at the Institute of Molecular Medicine and Experimental Immunology, University of Bonn, supported in part by SFB 704. We also acknowledge F. Frommer in helping to establish EAE-models.</p><p>This work was funded by SFB 704, BONFOR, KFO 177.</p><p>The authors have no conflicting financial interest.</p></ack><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettelli</surname><given-names>E.</given-names></name><name><surname>Korn</surname><given-names>T.</given-names></name><name><surname>Kuchroo</surname><given-names>V.K.</given-names></name></person-group><year>2007</year><article-title>Th17: the third member of the effector T cell trilogy</article-title>.<source>Curr. Opin. Immunol.</source><volume>19</volume>:<fpage>652</fpage>&#x02013;<lpage>657</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1016/j.coi.2007.07.020">10.1016/j.coi.2007.07.020</ext-link></comment><pub-id pub-id-type="pmid">17766098</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambon</surname><given-names>P.</given-names></name></person-group><year>1994</year><article-title>The retinoid signaling pathway: molecular and genetic analyses</article-title>.<source>Semin. Cell Biol.</source><volume>5</volume>:<fpage>115</fpage>&#x02013;<lpage>125</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1006/scel.1994.1015">10.1006/scel.1994.1015</ext-link></comment><pub-id pub-id-type="pmid">8068884</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chawla</surname><given-names>A.</given-names></name><name><surname>Barak</surname><given-names>Y.</given-names></name><name><surname>Nagy</surname><given-names>L.</given-names></name><name><surname>Liao</surname><given-names>D.</given-names></name><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Evans</surname><given-names>R.M.</given-names></name></person-group><year>2001</year><article-title>PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation</article-title>.<source>Nat. Med.</source><volume>7</volume>:<fpage>48</fpage>&#x02013;<lpage>52</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/83336">10.1038/83336</ext-link></comment><pub-id pub-id-type="pmid">11135615</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>R.B.</given-names></name><name><surname>Bishop-Bailey</surname><given-names>D.</given-names></name><name><surname>Estrada-Hernandez</surname><given-names>T.</given-names></name><name><surname>Hla</surname><given-names>T.</given-names></name><name><surname>Puddington</surname><given-names>L.</given-names></name><name><surname>Padula</surname><given-names>S.J.</given-names></name></person-group><year>2000</year><article-title>The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses</article-title>.<source>J. Immunol.</source><volume>164</volume>:<fpage>1364</fpage>&#x02013;<lpage>1371</lpage><pub-id pub-id-type="pmid">10640751</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cua</surname><given-names>D.J.</given-names></name><name><surname>Sherlock</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Murphy</surname><given-names>C.A.</given-names></name><name><surname>Joyce</surname><given-names>B.</given-names></name><name><surname>Seymour</surname><given-names>B.</given-names></name><name><surname>Lucian</surname><given-names>L.</given-names></name><name><surname>To</surname><given-names>W.</given-names></name><name><surname>Kwan</surname><given-names>S.</given-names></name><name><surname>Churakova</surname><given-names>T.</given-names></name><etal/></person-group><year>2003</year><article-title>Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain</article-title>.<source>Nature.</source><volume>421</volume>:<fpage>744</fpage>&#x02013;<lpage>748</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nature01355">10.1038/nature01355</ext-link></comment><pub-id pub-id-type="pmid">12610626</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diab</surname><given-names>A.</given-names></name><name><surname>Deng</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>J.D.</given-names></name><name><surname>Hussain</surname><given-names>R.Z.</given-names></name><name><surname>Phanavanh</surname><given-names>B.</given-names></name><name><surname>Lovett-Racke</surname><given-names>A.E.</given-names></name><name><surname>Drew</surname><given-names>P.D.</given-names></name><name><surname>Racke</surname><given-names>M.K.</given-names></name></person-group><year>2002</year><article-title>Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis</article-title>.<source>J. Immunol.</source><volume>168</volume>:<fpage>2508</fpage>&#x02013;<lpage>2515</lpage><pub-id pub-id-type="pmid">11859145</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>S.E.</given-names></name><name><surname>Ousman</surname><given-names>S.S.</given-names></name><name><surname>Sobel</surname><given-names>R.A.</given-names></name><name><surname>Zuniga</surname><given-names>L.</given-names></name><name><surname>Baranzini</surname><given-names>S.E.</given-names></name><name><surname>Youssef</surname><given-names>S.</given-names></name><name><surname>Crowell</surname><given-names>A.</given-names></name><name><surname>Loh</surname><given-names>J.</given-names></name><name><surname>Oksenberg</surname><given-names>J.</given-names></name><name><surname>Steinman</surname><given-names>L.</given-names></name></person-group><year>2007</year><article-title>Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity</article-title>.<source>J. Exp. Med.</source><volume>204</volume>:<fpage>321</fpage>&#x02013;<lpage>330</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1084/jem.20061839">10.1084/jem.20061839</ext-link></comment><pub-id pub-id-type="pmid">17261635</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinstein</surname><given-names>D.L.</given-names></name><name><surname>Galea</surname><given-names>E.</given-names></name><name><surname>Gavrilyuk</surname><given-names>V.</given-names></name><name><surname>Brosnan</surname><given-names>C.F.</given-names></name><name><surname>Whitacre</surname><given-names>C.C.</given-names></name><name><surname>Dumitrescu-Ozimek</surname><given-names>L.</given-names></name><name><surname>Landreth</surname><given-names>G.E.</given-names></name><name><surname>Pershadsingh</surname><given-names>H.A.</given-names></name><name><surname>Weinberg</surname><given-names>G.</given-names></name><name><surname>Heneka</surname><given-names>M.T.</given-names></name></person-group><year>2002</year><article-title>Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis</article-title>.<source>Ann. Neurol.</source><volume>51</volume>:<fpage>694</fpage>&#x02013;<lpage>702</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1002/ana.10206">10.1002/ana.10206</ext-link></comment><pub-id pub-id-type="pmid">12112074</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frohnert</surname><given-names>B.I.</given-names></name><name><surname>Hui</surname><given-names>T.Y.</given-names></name><name><surname>Bernlohr</surname><given-names>D.A.</given-names></name></person-group><year>1999</year><article-title>Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene</article-title>.<source>J. Biol. Chem.</source><volume>274</volume>:<fpage>3970</fpage>&#x02013;<lpage>3977</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1074/jbc.274.7.3970">10.1074/jbc.274.7.3970</ext-link></comment><pub-id pub-id-type="pmid">9933587</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghisletti</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Jepsen</surname><given-names>K.</given-names></name><name><surname>Benner</surname><given-names>C.</given-names></name><name><surname>Hardiman</surname><given-names>G.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.G.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name></person-group><year>2009</year><article-title>Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways</article-title>.<source>Genes Dev.</source><volume>23</volume>:<fpage>681</fpage>&#x02013;<lpage>693</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1101/gad.1773109">10.1101/gad.1773109</ext-link></comment><pub-id pub-id-type="pmid">19299558</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>C.K.</given-names></name><name><surname>Ogawa</surname><given-names>S.</given-names></name></person-group><year>2006</year><article-title>Combinatorial roles of nuclear receptors in inflammation and immunity</article-title>.<source>Natl. Rev. Immunol.</source><volume>6</volume>:<fpage>44</fpage>&#x02013;<lpage>55</lpage></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>L.E.</given-names></name><name><surname>Hatton</surname><given-names>R.D.</given-names></name><name><surname>Mangan</surname><given-names>P.R.</given-names></name><name><surname>Turner</surname><given-names>H.</given-names></name><name><surname>Murphy</surname><given-names>T.L.</given-names></name><name><surname>Murphy</surname><given-names>K.M.</given-names></name><name><surname>Weaver</surname><given-names>C.T.</given-names></name></person-group><year>2005</year><article-title>Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages</article-title>.<source>Nat. Immunol.</source><volume>6</volume>:<fpage>1123</fpage>&#x02013;<lpage>1132</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/ni1254">10.1038/ni1254</ext-link></comment><pub-id pub-id-type="pmid">16200070</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Barak</surname><given-names>Y.</given-names></name><name><surname>Hevener</surname><given-names>A.</given-names></name><name><surname>Olson</surname><given-names>P.</given-names></name><name><surname>Liao</surname><given-names>D.</given-names></name><name><surname>Le</surname><given-names>J.</given-names></name><name><surname>Nelson</surname><given-names>M.</given-names></name><name><surname>Ong</surname><given-names>E.</given-names></name><name><surname>Olefsky</surname><given-names>J.M.</given-names></name><name><surname>Evans</surname><given-names>R.M.</given-names></name></person-group><year>2003</year><article-title>Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle</article-title>.<source>Proc. Natl. Acad. Sci. USA.</source><volume>100</volume>:<fpage>15712</fpage>&#x02013;<lpage>15717</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1073/pnas.2536828100">10.1073/pnas.2536828100</ext-link></comment><pub-id pub-id-type="pmid">14660788</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heppner</surname><given-names>F.L.</given-names></name><name><surname>Greter</surname><given-names>M.</given-names></name><name><surname>Marino</surname><given-names>D.</given-names></name><name><surname>Falsig</surname><given-names>J.</given-names></name><name><surname>Raivich</surname><given-names>G.</given-names></name><name><surname>H&#x000f6;velmeyer</surname><given-names>N.</given-names></name><name><surname>Waisman</surname><given-names>A.</given-names></name><name><surname>R&#x000fc;licke</surname><given-names>T.</given-names></name><name><surname>Prinz</surname><given-names>M.</given-names></name><name><surname>Priller</surname><given-names>J.</given-names></name><etal/></person-group><year>2005</year><article-title>Experimental autoimmune encephalomyelitis repressed by microglial paralysis</article-title>.<source>Nat. Med.</source><volume>11</volume>:<fpage>146</fpage>&#x02013;<lpage>152</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nm1177">10.1038/nm1177</ext-link></comment><pub-id pub-id-type="pmid">15665833</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermann-Kleiter</surname><given-names>N.</given-names></name><name><surname>Gruber</surname><given-names>T.</given-names></name><name><surname>Lutz-Nicoladoni</surname><given-names>C.</given-names></name><name><surname>Thuille</surname><given-names>N.</given-names></name><name><surname>Fresser</surname><given-names>F.</given-names></name><name><surname>Labi</surname><given-names>V.</given-names></name><name><surname>Schiefermeier</surname><given-names>N.</given-names></name><name><surname>Warnecke</surname><given-names>M.</given-names></name><name><surname>Huber</surname><given-names>L.</given-names></name><name><surname>Villunger</surname><given-names>A.</given-names></name><etal/></person-group><year>2008</year><article-title>The nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-dependent autoimmunity</article-title>.<source>Immunity.</source><volume>29</volume>:<fpage>205</fpage>&#x02013;<lpage>216</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1016/j.immuni.2008.06.008">10.1016/j.immuni.2008.06.008</ext-link></comment><pub-id pub-id-type="pmid">18701084</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J.T.</given-names></name><name><surname>Welch</surname><given-names>J.S.</given-names></name><name><surname>Ricote</surname><given-names>M.</given-names></name><name><surname>Binder</surname><given-names>C.J.</given-names></name><name><surname>Willson</surname><given-names>T.M.</given-names></name><name><surname>Kelly</surname><given-names>C.</given-names></name><name><surname>Witztum</surname><given-names>J.L.</given-names></name><name><surname>Funk</surname><given-names>C.D.</given-names></name><name><surname>Conrad</surname><given-names>D.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name></person-group><year>1999</year><article-title>Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase</article-title>.<source>Nature.</source><volume>400</volume>:<fpage>378</fpage>&#x02013;<lpage>382</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/22572">10.1038/22572</ext-link></comment><pub-id pub-id-type="pmid">10432118</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>M.</given-names></name><name><surname>Br&#x000fc;stle</surname><given-names>A.</given-names></name><name><surname>Reinhard</surname><given-names>K.</given-names></name><name><surname>Guralnik</surname><given-names>A.</given-names></name><name><surname>Walter</surname><given-names>G.</given-names></name><name><surname>Mahiny</surname><given-names>A.</given-names></name><name><surname>von L&#x000f6;w</surname><given-names>E.</given-names></name><name><surname>Lohoff</surname><given-names>M.</given-names></name></person-group><year>2008</year><article-title>IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype</article-title>.<source>Proc. Natl. Acad. Sci. USA.</source><volume>105</volume>:<fpage>20846</fpage>&#x02013;<lpage>20851</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1073/pnas.0809077106">10.1073/pnas.0809077106</ext-link></comment><pub-id pub-id-type="pmid">19088203</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanov</surname><given-names>I.I.</given-names></name><name><surname>McKenzie</surname><given-names>B.S.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Tadokoro</surname><given-names>C.E.</given-names></name><name><surname>Lepelley</surname><given-names>A.</given-names></name><name><surname>Lafaille</surname><given-names>J.J.</given-names></name><name><surname>Cua</surname><given-names>D.J.</given-names></name><name><surname>Littman</surname><given-names>D.R.</given-names></name></person-group><year>2006</year><article-title>The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells</article-title>.<source>Cell.</source><volume>126</volume>:<fpage>1121</fpage>&#x02013;<lpage>1133</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1016/j.cell.2006.07.035">10.1016/j.cell.2006.07.035</ext-link></comment><pub-id pub-id-type="pmid">16990136</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>M.</given-names></name><name><surname>Eshima</surname><given-names>Y.</given-names></name><name><surname>Kagechika</surname><given-names>H.</given-names></name></person-group><year>2003</year><article-title>Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors</article-title>.<source>Int. Immunol.</source><volume>15</volume>:<fpage>1017</fpage>&#x02013;<lpage>1025</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1093/intimm/dxg101">10.1093/intimm/dxg101</ext-link></comment><pub-id pub-id-type="pmid">12882839</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klotz</surname><given-names>L.</given-names></name><name><surname>Dani</surname><given-names>I.</given-names></name><name><surname>Edenhofer</surname><given-names>F.</given-names></name><name><surname>Nolden</surname><given-names>L.</given-names></name><name><surname>Evert</surname><given-names>B.</given-names></name><name><surname>Paul</surname><given-names>B.</given-names></name><name><surname>Kolanus</surname><given-names>W.</given-names></name><name><surname>Klockgether</surname><given-names>T.</given-names></name><name><surname>Knolle</surname><given-names>P.</given-names></name><name><surname>Diehl</surname><given-names>L.</given-names></name></person-group><year>2007</year><article-title>Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy</article-title>.<source>J. Immunol.</source><volume>178</volume>:<fpage>2122</fpage>&#x02013;<lpage>2131</lpage><pub-id pub-id-type="pmid">17277116</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P.P.</given-names></name><name><surname>Fitzpatrick</surname><given-names>D.R.</given-names></name><name><surname>Beard</surname><given-names>C.</given-names></name><name><surname>Jessup</surname><given-names>H.K.</given-names></name><name><surname>Lehar</surname><given-names>S.</given-names></name><name><surname>Makar</surname><given-names>K.W.</given-names></name><name><surname>P&#x000e9;rez-Melgosa</surname><given-names>M.</given-names></name><name><surname>Sweetser</surname><given-names>M.T.</given-names></name><name><surname>Schlissel</surname><given-names>M.S.</given-names></name><name><surname>Nguyen</surname><given-names>S.</given-names></name><etal/></person-group><year>2001</year><article-title>A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival</article-title>.<source>Immunity.</source><volume>15</volume>:<fpage>763</fpage>&#x02013;<lpage>774</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1016/S1074-7613(01)00227-8">10.1016/S1074-7613(01)00227-8</ext-link></comment><pub-id pub-id-type="pmid">11728338</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lochner</surname><given-names>M.</given-names></name><name><surname>Peduto</surname><given-names>L.</given-names></name><name><surname>Cherrier</surname><given-names>M.</given-names></name><name><surname>Sawa</surname><given-names>S.</given-names></name><name><surname>Langa</surname><given-names>F.</given-names></name><name><surname>Varona</surname><given-names>R.</given-names></name><name><surname>Riethmacher</surname><given-names>D.</given-names></name><name><surname>Si-Tahar</surname><given-names>M.</given-names></name><name><surname>Di Santo</surname><given-names>J.P.</given-names></name><name><surname>Eberl</surname><given-names>G.</given-names></name></person-group><year>2008</year><article-title>In vivo equilibrium of proinflammatory IL-17<sup>+</sup> and regulatory IL-10<sup>+</sup> Foxp3<sup>+</sup> ROR&#x003b3;t<sup>+</sup> T cells</article-title>.<source>J. Exp. Med.</source><volume>205</volume>:<fpage>1381</fpage>&#x02013;<lpage>1393</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1084/jem.20080034">10.1084/jem.20080034</ext-link></comment><pub-id pub-id-type="pmid">18504307</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lock</surname><given-names>C.</given-names></name><name><surname>Hermans</surname><given-names>G.</given-names></name><name><surname>Pedotti</surname><given-names>R.</given-names></name><name><surname>Brendolan</surname><given-names>A.</given-names></name><name><surname>Schadt</surname><given-names>E.</given-names></name><name><surname>Garren</surname><given-names>H.</given-names></name><name><surname>Langer-Gould</surname><given-names>A.</given-names></name><name><surname>Strober</surname><given-names>S.</given-names></name><name><surname>Cannella</surname><given-names>B.</given-names></name><name><surname>Allard</surname><given-names>J.</given-names></name><etal/></person-group><year>2002</year><article-title>Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis</article-title>.<source>Nat. Med.</source><volume>8</volume>:<fpage>500</fpage>&#x02013;<lpage>508</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nm0502-500">10.1038/nm0502-500</ext-link></comment><pub-id pub-id-type="pmid">11984595</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manel</surname><given-names>N.</given-names></name><name><surname>Unutmaz</surname><given-names>D.</given-names></name><name><surname>Littman</surname><given-names>D.R.</given-names></name></person-group><year>2008</year><article-title>The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat</article-title>.<source>Nat. Immunol.</source><volume>9</volume>:<fpage>641</fpage>&#x02013;<lpage>649</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/ni.1610">10.1038/ni.1610</ext-link></comment><pub-id pub-id-type="pmid">18454151</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucida</surname><given-names>D.</given-names></name><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>G.</given-names></name><name><surname>Turovskaya</surname><given-names>O.</given-names></name><name><surname>Scott</surname><given-names>I.</given-names></name><name><surname>Kronenberg</surname><given-names>M.</given-names></name><name><surname>Cheroutre</surname><given-names>H.</given-names></name></person-group><year>2007</year><article-title>Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid</article-title>.<source>Science.</source><volume>317</volume>:<fpage>256</fpage>&#x02013;<lpage>260</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1126/science.1145697">10.1126/science.1145697</ext-link></comment><pub-id pub-id-type="pmid">17569825</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>C.A.</given-names></name><name><surname>Langrish</surname><given-names>C.L.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Blumenschein</surname><given-names>W.</given-names></name><name><surname>McClanahan</surname><given-names>T.</given-names></name><name><surname>Kastelein</surname><given-names>R.A.</given-names></name><name><surname>Sedgwick</surname><given-names>J.D.</given-names></name><name><surname>Cua</surname><given-names>D.J.</given-names></name></person-group><year>2003</year><article-title>Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation</article-title>.<source>J. Exp. Med.</source><volume>198</volume>:<fpage>1951</fpage>&#x02013;<lpage>1957</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1084/jem.20030896">10.1084/jem.20030896</ext-link></comment><pub-id pub-id-type="pmid">14662908</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niino</surname><given-names>M.</given-names></name><name><surname>Iwabuchi</surname><given-names>K.</given-names></name><name><surname>Kikuchi</surname><given-names>S.</given-names></name><name><surname>Ato</surname><given-names>M.</given-names></name><name><surname>Morohashi</surname><given-names>T.</given-names></name><name><surname>Ogata</surname><given-names>A.</given-names></name><name><surname>Tashiro</surname><given-names>K.</given-names></name><name><surname>Ono&#x000e9;</surname><given-names>K.</given-names></name></person-group><year>2001</year><article-title>Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma</article-title>.<source>J. Neuroimmunol.</source><volume>116</volume>:<fpage>40</fpage>&#x02013;<lpage>48</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1016/S0165-5728(01)00285-5">10.1016/S0165-5728(01)00285-5</ext-link></comment><pub-id pub-id-type="pmid">11311328</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurieva</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>X.O.</given-names></name><name><surname>Martinez</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Panopoulos</surname><given-names>A.D.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Schluns</surname><given-names>K.</given-names></name><name><surname>Tian</surname><given-names>Q.</given-names></name><name><surname>Watowich</surname><given-names>S.S.</given-names></name><name><surname>Jetten</surname><given-names>A.M.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name></person-group><year>2007</year><article-title>Essential autocrine regulation by IL-21 in the generation of inflammatory T cells</article-title>.<source>Nature.</source><volume>448</volume>:<fpage>480</fpage>&#x02013;<lpage>483</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nature05969">10.1038/nature05969</ext-link></comment><pub-id pub-id-type="pmid">17581589</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.O.</given-names></name><name><surname>Chang</surname><given-names>S.H.</given-names></name><name><surname>Nurieva</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Y.H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hood</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Tian</surname><given-names>Q.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name></person-group><year>2005</year><article-title>A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17</article-title>.<source>Nat. Immunol.</source><volume>6</volume>:<fpage>1133</fpage>&#x02013;<lpage>1141</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/ni1261">10.1038/ni1261</ext-link></comment><pub-id pub-id-type="pmid">16200068</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>G.</given-names></name><name><surname>Fong</surname><given-names>A.L.</given-names></name><name><surname>Ogawa</surname><given-names>S.</given-names></name><name><surname>Gamliel</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>A.C.</given-names></name><name><surname>Perissi</surname><given-names>V.</given-names></name><name><surname>Rose</surname><given-names>D.W.</given-names></name><name><surname>Willson</surname><given-names>T.M.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.G.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name></person-group><year>2005</year><article-title>A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma</article-title>.<source>Nature.</source><volume>437</volume>:<fpage>759</fpage>&#x02013;<lpage>763</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nature03988">10.1038/nature03988</ext-link></comment><pub-id pub-id-type="pmid">16127449</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana</surname><given-names>F.J.</given-names></name><name><surname>Basso</surname><given-names>A.S.</given-names></name><name><surname>Iglesias</surname><given-names>A.H.</given-names></name><name><surname>Korn</surname><given-names>T.</given-names></name><name><surname>Farez</surname><given-names>M.F.</given-names></name><name><surname>Bettelli</surname><given-names>E.</given-names></name><name><surname>Caccamo</surname><given-names>M.</given-names></name><name><surname>Oukka</surname><given-names>M.</given-names></name><name><surname>Weiner</surname><given-names>H.L.</given-names></name></person-group><year>2008</year><article-title>Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor</article-title>.<source>Nature.</source><volume>453</volume>:<fpage>65</fpage>&#x02013;<lpage>71</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nature06880">10.1038/nature06880</ext-link></comment><pub-id pub-id-type="pmid">18362915</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reboldi</surname><given-names>A.</given-names></name><name><surname>Coisne</surname><given-names>C.</given-names></name><name><surname>Baumjohann</surname><given-names>D.</given-names></name><name><surname>Benvenuto</surname><given-names>F.</given-names></name><name><surname>Bottinelli</surname><given-names>D.</given-names></name><name><surname>Lira</surname><given-names>S.</given-names></name><name><surname>Uccelli</surname><given-names>A.</given-names></name><name><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name><surname>Engelhardt</surname><given-names>B.</given-names></name><name><surname>Sallusto</surname><given-names>F.</given-names></name></person-group><year>2009</year><article-title>C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE</article-title>.<source>Nat. Immunol.</source><volume>10</volume>:<fpage>514</fpage>&#x02013;<lpage>523</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/ni.1716">10.1038/ni.1716</ext-link></comment><pub-id pub-id-type="pmid">19305396</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straus</surname><given-names>D.S.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name></person-group><year>2007</year><article-title>Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms</article-title>.<source>Trends Immunol.</source><volume>28</volume>:<fpage>551</fpage>&#x02013;<lpage>558</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1016/j.it.2007.09.003">10.1016/j.it.2007.09.003</ext-link></comment><pub-id pub-id-type="pmid">17981503</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szatmari</surname><given-names>I.</given-names></name><name><surname>T&#x000f6;r&#x000f6;csik</surname><given-names>D.</given-names></name><name><surname>Agostini</surname><given-names>M.</given-names></name><name><surname>Nagy</surname><given-names>T.</given-names></name><name><surname>Gurnell</surname><given-names>M.</given-names></name><name><surname>Barta</surname><given-names>E.</given-names></name><name><surname>Chatterjee</surname><given-names>K.</given-names></name><name><surname>Nagy</surname><given-names>L.</given-names></name></person-group><year>2007</year><article-title>PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism</article-title>.<source>Blood.</source><volume>110</volume>:<fpage>3271</fpage>&#x02013;<lpage>3280</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1182/blood-2007-06-096222">10.1182/blood-2007-06-096222</ext-link></comment><pub-id pub-id-type="pmid">17664351</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzartos</surname><given-names>J.S.</given-names></name><name><surname>Friese</surname><given-names>M.A.</given-names></name><name><surname>Craner</surname><given-names>M.J.</given-names></name><name><surname>Palace</surname><given-names>J.</given-names></name><name><surname>Newcombe</surname><given-names>J.</given-names></name><name><surname>Esiri</surname><given-names>M.M.</given-names></name><name><surname>Fugger</surname><given-names>L.</given-names></name></person-group><year>2008</year><article-title>Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis</article-title>.<source>Am. J. Pathol.</source><volume>172</volume>:<fpage>146</fpage>&#x02013;<lpage>155</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.2353/ajpath.2008.070690">10.2353/ajpath.2008.070690</ext-link></comment><pub-id pub-id-type="pmid">18156204</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderhoek</surname><given-names>J.Y.</given-names></name></person-group><year>1988</year><article-title>Role of the 15-lipoxygenase in the immune system</article-title>.<source>Ann. N. Y. Acad. Sci.</source><volume>524</volume>:<fpage>240</fpage>&#x02013;<lpage>251</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1111/j.1749-6632.1988.tb38547.x">10.1111/j.1749-6632.1988.tb38547.x</ext-link></comment><pub-id pub-id-type="pmid">3132881</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhoen</surname><given-names>M.</given-names></name><name><surname>Hirota</surname><given-names>K.</given-names></name><name><surname>Westendorf</surname><given-names>A.M.</given-names></name><name><surname>Buer</surname><given-names>J.</given-names></name><name><surname>Dumoutier</surname><given-names>L.</given-names></name><name><surname>Renauld</surname><given-names>J.C.</given-names></name><name><surname>Stockinger</surname><given-names>B.</given-names></name></person-group><year>2008</year><article-title>The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins</article-title>.<source>Nature.</source><volume>453</volume>:<fpage>106</fpage>&#x02013;<lpage>109</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nature06881">10.1038/nature06881</ext-link></comment><pub-id pub-id-type="pmid">18362914</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Anderson</surname><given-names>D.E.</given-names></name><name><surname>Baecher-Allan</surname><given-names>C.</given-names></name><name><surname>Hastings</surname><given-names>W.D.</given-names></name><name><surname>Bettelli</surname><given-names>E.</given-names></name><name><surname>Oukka</surname><given-names>M.</given-names></name><name><surname>Kuchroo</surname><given-names>V.K.</given-names></name><name><surname>Hafler</surname><given-names>D.A.</given-names></name></person-group><year>2008</year><article-title>IL-21 and TGF-beta are required for differentiation of human T(H)17 cells</article-title>.<source>Nature.</source><volume>454</volume>:<fpage>350</fpage>&#x02013;<lpage>352</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nature07021">10.1038/nature07021</ext-link></comment><pub-id pub-id-type="pmid">18469800</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Weiner</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Smith</surname><given-names>A.J.</given-names></name><name><surname>Huss</surname><given-names>D.J.</given-names></name><name><surname>Winger</surname><given-names>R.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Cravens</surname><given-names>P.D.</given-names></name><name><surname>Racke</surname><given-names>M.K.</given-names></name><name><surname>Lovett-Racke</surname><given-names>A.E.</given-names></name></person-group><year>2009</year><article-title>T-bet is essential for encephalitogenicity of both Th1 and Th17 cells</article-title>.<source>J. Exp. Med.</source><volume>206</volume>:<fpage>1549</fpage>&#x02013;<lpage>1564</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1084/jem.20082584">10.1084/jem.20082584</ext-link></comment><pub-id pub-id-type="pmid">19546248</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>D.</given-names></name><name><surname>Cheung</surname><given-names>J.</given-names></name><name><surname>Scheerens</surname><given-names>H.</given-names></name><name><surname>Poulet</surname><given-names>F.</given-names></name><name><surname>McClanahan</surname><given-names>T.</given-names></name><name><surname>McKenzie</surname><given-names>B.</given-names></name><name><surname>Kleinschek</surname><given-names>M.A.</given-names></name><name><surname>Owyang</surname><given-names>A.</given-names></name><name><surname>Mattson</surname><given-names>J.</given-names></name><name><surname>Blumenschein</surname><given-names>W.</given-names></name><etal/></person-group><year>2006</year><article-title>IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6</article-title>.<source>J. Clin. Invest.</source><volume>116</volume>:<fpage>1310</fpage>&#x02013;<lpage>1316</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1172/JCI21404">10.1172/JCI21404</ext-link></comment><pub-id pub-id-type="pmid">16670770</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Lopes</surname><given-names>J.E.</given-names></name><name><surname>Chong</surname><given-names>M.M.</given-names></name><name><surname>Ivanov</surname><given-names>I.I.</given-names></name><name><surname>Min</surname><given-names>R.</given-names></name><name><surname>Victora</surname><given-names>G.D.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Rubtsov</surname><given-names>Y.P.</given-names></name><name><surname>Rudensky</surname><given-names>A.Y.</given-names></name><etal/></person-group><year>2008</year><article-title>TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function</article-title>.<source>Nature.</source><volume>453</volume>:<fpage>236</fpage>&#x02013;<lpage>240</lpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1038/nature06878">10.1038/nature06878</ext-link></comment><pub-id pub-id-type="pmid">18368049</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p><def-list><title>Abbreviations used:</title><def-item><term>ChIP</term><def><p>chromatin immunoprecipitation</p></def></def-item><def-item><term>CNS</term><def><p>central nervous system</p></def></def-item><def-item><term>EAE</term><def><p>experimental autoimmune encephalomyelitis</p></def></def-item><def-item><term>HC</term><def><p>healthy control</p></def></def-item><def-item><term>HODE</term><def><p>hydroxyoctadecadienoic acid</p></def></def-item><def-item><term>MS</term><def><p>multiple sclerosis</p></def></def-item><def-item><term>NCoR</term><def><p>nuclear corepressor</p></def></def-item><def-item><term>PIO</term><def><p>pioglitazone</p></def></def-item><def-item><term>PPAR &#x003b3;</term><def><p>peroxisome proliferator&#x02013;activated receptor &#x003b3;</p></def></def-item><def-item><term>PPRE</term><def><p>PPAR response element</p></def></def-item><def-item><term>RA</term><def><p>retinoic acid</p></def></def-item><def-item><term>ROR&#x003b3;t</term><def><p>RA receptor&#x02013;related orphan receptor &#x003b3;t</p></def></def-item><def-item><term>SMRT</term><def><p>silencing mediator for retinoid and thyroid hormone receptors</p></def></def-item></def-list></p></fn></fn-group></back></article>